
    
      OUTLINE:

      Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of weeks 0, 3, and
      6 and methotrexate IV, vinblastine IV, doxorubicin IV, and cisplatin IV on day 1 of weeks 0,
      2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients also
      receive pegfilgrastim subcutaneously (SC) on day 1 or 2 of weeks 0, 2, 4, and 6 in the
      absence of disease progression or unacceptable toxicity. Patients then undergo standard of
      care radical cystectomy.

      After completion of study treatment, patients are followed up about 1 month after surgery and
      then every 3-6 months for 2 years.
    
  